# Adaptive Phage Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adaptive-phage-therapeutics

- Industry: Biotechnology
- Headquarters: Gaithersburg, US
- Total disclosed funding: $55M
- Latest round: Series B (May 25, 2023)
- Investors on record: 3

## About

Founded in 2016 by Carl Merril MD and Gregory Merril and based in Maryland, US, Adaptive Phage Therapeutics, Inc. operates as a biotechnology company that offers a therapeutic response for patients with multi-drug-resistant (MDR) pathogenic bacteria. In March 2024, BiomX Inc., a portfolio company of Mirae Asset Global Investments, Deerfield Management, RTW Investments, Nantahala Capital Management, Cystic Fibrosis Foundation, OrbiMed Advisors, and AMR Action Fund, acquired Adaptive Phage Therapeutics, Inc. from Mayo Clinic, Deerfield Management, and AMR Action Fund.

The company’s primary product, PhageBank™, addresses this challenge by utilizing an expanding library of bacteriophages, or phages, which offer broad-spectrum and polymicrobial coverage against resistant bacteria. The PhageBank™ phages are selected using a proprietary phage susceptibility assay developed in collaboration with Mayo Clinic Laboratories.

## Funding rounds

- Series B, May 25, 2023, $12M — Deerfield Management, AMR Action Fund
- Series B, Apr 4, 2022, $20M — AMR Action Fund
- Series B, May 11, 2021, $23M — Mayo Clinic, Deerfield Management

## Investors

- Mayo Clinic — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B
- AMR Action Fund (https://capitalatlas.ai/funds/amr-action-fund) — Series B